文献速递银屑病与炎症性皮肤病皮肤肿瘤

银屑病生物制剂患者的年龄适配癌症筛查:队列研究

Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension.
PubMed 文献 · J Am Acad Dermatol · 2020-10-23

该回顾性队列研究利用Optum电子健康记录数据,比较了接受生物制剂治疗的银屑病患者与一般人群及高血压患者的宫颈癌、乳腺癌和结肠癌筛查率。结果显示,银屑病生物制剂患者的宫颈癌和结肠癌筛查率高于一般人群,但乳腺癌和结肠癌筛查率低于高血压患者,提示可能未充分接受年龄适配的癌症筛查。

要点

  • 银屑病生物制剂患者宫颈癌和结肠癌筛查率高于一般人群。
  • 银屑病生物制剂患者乳腺癌和结肠癌筛查率低于高血压患者。
  • 应关注银屑病生物制剂患者的年龄适配癌症筛查,尤其是乳腺癌和结肠癌。

核心结论

  • 接受生物制剂治疗的银屑病患者可能未充分接受年龄适配的癌症筛查,尤其是乳腺癌和结肠癌。

研究设计与样本

  • 回顾性队列研究,使用Optum去标识电子健康记录数据集,比较银屑病生物制剂患者与匹配的一般人群和高血压患者的癌症筛查率。

主要发现

  • 与无银屑病一般人群相比,银屑病生物制剂患者的宫颈癌筛查率更高(aHR 1.09;95%CI 1.02-1.16)。
  • 与无银屑病一般人群相比,银屑病生物制剂患者的结肠癌筛查率更高(aHR 1.10;95%CI 1.02-1.18)。
  • 与高血压患者相比,银屑病生物制剂患者的乳腺癌筛查率更低(aHR 0.88;95%CI 0.83-0.94)。
  • 与高血压患者相比,银屑病生物制剂患者的结肠癌筛查率更低(aHR 0.89;95%CI 0.83-0.95)。

临床怎么用

  • 对接受生物制剂治疗的银屑病患者,应主动评估并促进其完成年龄适配的癌症筛查,特别是乳腺癌和结肠癌筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is associated with increased risk of developing and dying from cancer. OBJECTIVE: To evaluate whether psoriasis patients who are prescribed biologics receive the recommended screening for cervical, breast, and colon cancer. METHODS: We conducted a retrospective cohort study using the Optum deidentified Electronic Health Record data set. Incidence rates for cervical, breast, and colon cancer screening were compared between psoriasis patients who were prescribed biologics and 2 matched comparator cohorts: general patient population and patients being managed for hypertension. Multivariable Cox proportional hazards regression was performed to assess for differences in the rates of cancer screening. RESULTS: Compared with those in the general population without psoriasis, psoriasis patients who were prescribed biologics had higher screening rates for cervical cancer (adjusted hazard ratio [aHR] 1.09; 95% confidence interval [CI] 1.02-1.16) and colon cancer (aHR 1.10; 95% CI 1.02-1.18). Compared with those with hypertension, patients with psoriasis who were prescribed biologics had lower screening rates for breast cancer (aHR 0.88; 95% CI 0.83-0.94) and colon cancer (aHR 0.89; 95% CI 0.83-0.95). CONCLUSIONS AND RELEVANCE: Patients with psoriasis who are prescribed biologic therapies may not be receiving adequate age-appropriate cancer screening, especially for breast and colon cancer.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Barbieri JS, Wang S, Ogdie AR, et al. Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension. J Am Acad Dermatol. 2020. PMID: 33470207. doi:10.1016/j.jaad.2020.10.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。